事務局　提出

第6回臨床研究専門委員会	資料　5
平成20年2月13日	

臨床研究登録の動向について

介入的臨床研究の計画の登録と公表についての状況について（案）

医政局研究開発振興課

１．現状及び改正の方向性

(1) 現状について

現行の指針においては、以下の規定により、公表について臨床研究機関の長の努力義務としている。

（臨床研究に関する倫理指針より）

第２　研究者等の責務等

２ 臨床研究機関の長の責務等

(5) 臨床研究計画等の公開

臨床研究機関の長は、臨床研究計画及び臨床研究の成果を公開するよう努めるものとする。

(2) 改正の方向性について

指針の改正においては、現行の指針の努力義務に加えて、特に介入研究については、後述の世界各国の情勢も踏まえながら、公開データベースへの登録について検討する必要があるのではないか。

(3) 国内の臨床試験登録体制について

臨床試験に関して国内では以下の機関において、無料で登録・公開を行っている。

① UMIN 臨床試験登録システム

大学病院医療情報ネットワーク(UMIN)が運用する臨床試験登録サイトであり、すべての臨床試験を登録対象としている。主に医師が実施する臨床試験が登録されている。

② JapicCTI

財団法人日本医薬情報センター(JAPIC)が運用する臨床試験登録サイトであり、医薬品に係る臨床試験を登録対象としている。主に企業が実施する治験に係る情報が登録されている。

③ 日本医師会治験促進センター「臨床試験登録システム」

社団法人日本医師会治験促進センターが運用する臨床試験登録サイトであり、医師主導治験及び医療機器に係る企業実施の治験を登録対象としている。

④　国立保健医療科学院ポータルサイト

臨床試験の登録機関ではないが、上記３つの機関にある情報を横断的に検索することが可能なサイト。国立保健医療科学院が平成１９年１０月より運用を開始している。

①②③の登録システムの集合体としてＷＨＯのプライマリーレジスター（登録機関）とする準備・検討中「Japan Clinical Trial Registers Network」。

２．登録に関する国際的な動向

(1) ヘルシンキ宣言への結果公表義務の追加（2000 年　エジンバラ改訂）

2000 年のエジンバラ改訂において、ヘルシンキ宣言には以下の 27 条が追加され、臨床研究において､ネガティブ結果も含めた結果の公表が求められることとなった。

> ヘルシンキ宣言　第 27 条
>
> 著者および発行者は倫理的な義務を負っている。研究結果の刊行に際し、研究者は結果の正確さを保つよう義務づけられている｡ネガティブな結果もポジティブな結果と同様に、刊行または他の方法で公表利用されなければならない｡この刊行物中には､資金提供の財源､関連組織との関わりおよび可能性のあるすべての利害関係の衝突が明示されていなければならない｡この宣言が策定した原則に沿わない実験報告書は、公刊のために受理されてはならない

(2) 国際医学雑誌編集者会議（ICMJE）の声明の発表

ICMJE が 2004 年に声明を発表している。内容は、被験者のエントリー開始前に公的な臨床試験公表データベースへの登録を行っていない研究については､Lancet 等 ICMJE に加盟している 11 の医学雑誌への掲載を認めないというもの。

(3) WHO の取り組み

臨床研究の登録に対する呼びかけを実施している。2005 年 11 月開催の WHO の登録プラットホーム諮問委員会において、次の要件を規定している。結果の公表の在り方については、議論が継続している。

- すべての介入研究を登録することは、科学的、倫理的及びモラルとしての責務である。すべての介入的臨床研究は登録されるべきである
  ※　米国の法制では、第Ｉ相や探索試験は登録対象から除くことになっている。
- 最低 20 項目の登録事項について登録し、公表されるべきである。

ＷＨＯが 2005 年の WHO 総会決議に基づき、各国の登録機関とのネットワークを構築しているところ。

(4) 米国において立法措置

2007 年 9 月 27 日に公衆衛生サービス法を改正する公法が施行され、2007 年 12 月 27 日以降に実施するＦＤＡ規制の対象となる医薬品・医療機器の比較試験（第Ⅱ相以上）については、公開データベース（clinicaltrials.gov）への登録が義務づけられ、罰則規定も設けられた。（結果の公表に関しては今後の課題）

３．今後の対応について

(1) 指針における公開データベースへの登録の明示

① ヘルシンキ宣言、ＷＨＯの取り組み、米国の立法措置の動向を踏まえると、日本においても登録データベースの構築などの体制が整ったことから、改正後の臨床研究に関する倫理指針においては、方向性として、臨床研究のうち介入研究について登録データベース（UMIN, JAPIC, 日本医師会）への登録を明示するべきではないか。

② 登録義務を明示する対象として、

- すべての介入研究とするか（WHO の取り組み、ICMJE の勧告）
- 以下の研究の登録を義務づけ、その他を努力義務とするか
  - ー　医薬品・医療機器を用いた研究に限るか（米国の法制及び治験制度との整合性）
  - ー　さらに、探索試験を除くか（米国の法制との整合性）
- すべての介入研究を努力義務とするか

についての検討が必要。また、厚生労働省等への個別の計画の報告との関係の整理も必要。

(2) 登録を実施する者について

① ＷＨＯ及び米国の法制においては、研究の実施責任者（スポンサー）又は、principal investigator（研究責任医師）とするのが適当とされている。

② 科研費等の申請要件であるとから、倫理審査委員会に諮る前に登録する実態もあることから、日本においては、個々の研究者等（研究班の主任研究者等が一括して行う場合を含む）又は臨床研究機関の長としてはどうか。

(3) 研究者等に関するメリット・デメリットについて

① 被験者の募集等において活用されうること。

② 国内データベースへの登録が、国際的な医学雑誌への掲載に繋がること。

③ 無料であるが、手続きが増えること（→簡素化がどこまで可能か）。

④ 研究のオリジナリティーの確保に対する不安があること

別 表

WHO 会議報告からの抜粋

臨床試験の登録基準に関する WHO 技術諮問会議（2005 年 4 月 25 日～27 日）

「最小限のデータセット」

データ項目

	データ項目	
1.	固有の試験番号	
2.	臨床試験の登録日	
3.	二次 ID	
4.	資金源	
5.	主要スポンサー	
6.	副次スポンサー	
7.	試験の連絡窓口	一般からの問い合わせ先
8.	研究の連絡窓口	治験責任医師
9.	試験の標題	簡潔な標題
10.	試験の正式な科学的標題	試験結果に影響を及ぼす介入方法
11.	倫理委員会による審査	諾/否
12.	試験条件	
13.	介入	介入期間を含む
14.	主な組み入れ/除外基準	
15.	試験の種類	リストから選択（現在 clinicaltrials.gov 登録システムで入手可能）
16.	試験開始予定日	最初の被験者組み入れ予定日
17.	目標症例数	
18.	症例登録状況	情報の有無（あり/なし） 「あり」の場合は、その情報にリンク
19.	主要評価項目	観察時期または観察期間を含む
20.	主な副次評価項目	

（参考）　臨床研究計画の登録及び公表に関する意見について

WHOの登録データベースに関する情報サイトその他によれば、臨床研究計画の公表については以下のような意見があるとされている。

(1) Publication biasの観点

臨床研究の良好な結果のみが公表され、ネガティブなデータが公表されず、科学的に公平な評価を妨げるのみならず、被験者にとって不利な情報が知らされないリスクを防止する効果。

(2) 研究情報の透明性及び倫理

介入研究は、治療効果への期待と同時に被験者に身体的・精神的負担を課す可能性があるものであることから、研究計画や進捗状況を公表し、被験者に対しての情報提供の責務を果たすべきという意見。

(3) 研究に関する秘密・知財の漏洩

研究計画の公表は研究に関するは発明等の知財の漏洩につながり、研究成果を他人に盗用される危険性が増すのではないか。（Intervention(s), Primary Outcomes, Key Secondary Outcomes, Scientific Title, and Sample Sizeの5項目については、後日登録項目を提出するという方法がWHOでは検討されている。）

(4) 学問の自由や業務負担

研究に公表義務のような規制をかけることは、手続き等の手間を増やし、同時に学問の自由を制限することにつながるのではないか。

(5) 被験者の参加

研究者からみて被験者のリクルートが容易になる。臨床研究の検索が可能となり、被験者にとって必要な研究に参加しやすくなる。

DEPARTMENT OF RESEARCH POLICY AND COOPERATION WORLD HEALTH ORGANIZATION

International Clinical Trials Registry Platform

Scientific Advisory Group

Report of Meeting, 17 - 18 November 2005

Geneva, Switzerland

--- FINAL VERSION ---

February 24, 2006

Note:

- This report summarizes the discussions and advice of the Scientific Advisory Group.
- Differing views were expressed on certain topics, as noted in the text.
- **Formal policies of the Registry Platform may differ from those stated here.**
- Please refer to the Registry Platform website http://www.who.int/ictrp for definitive policies.

List of Participants

SAG Co-Chairs (2)

- **Kay Dickersin**, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- **Richard Horton**, The Lancet, London, United Kingdom

SAG Members (15)

- **Gerd Antes**, Deutsches Cochrane Zentrum, Freiburg, Germany
- **Chris Chute**, Mayo Clinic, Rochester, Minnesota, United States of America
- **Francis P. Crawley**, Good Clinical Practice Alliance, Kessel-Lo, Belgium
- **Jeffrey M. Drazen**, New England Journal of Medicine, Boston, Massachusetts, United States of America
- **Davina Ghersi**, NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
- **Anne Greenwood**, Current Science Group, London, United Kingdom
- **Karmela Krleza-Jeric**, Randomized Controlled Trials, Canadian Institutes of Health Research, Ottawa, Ontario, Canada
- **Rebecca Kush**, Clinical Data Interchange Standards Consortium (CDISC), Austin, Texas, United States of America
- **Frank W. Rockhold**, GlaxoSmithKline, United States of America
- **Masako Nishikawa**, Department of Technology Assessment and Biostatistics, National Institute of Public Health, Japan
- **Marc Taylor**, UK Department of Health, Leeds, United Kingdom
- **Jimmy Volmink**, University of Cape Town, Cape Town, South Africa
- **Liz Wager**, Sideview Consulting, Bucks, United Kingdom
- **Janet Wale**, Cochrane Consumer Network (CCNet), Burwood, VIC, Australia
- **Deborah Zarin**, ClinicalTrials.gov, Bethesda, Maryland, United States of America

WHO Staff

- **Esther Awit**
- **Metin Gülmezoglu**
- **Ghassan Karam**
- **Tikki Pang**
- **Ida Sim** (Project Coordinator)
- **Patrick Unterlerchner**

Charge to the Scientific Advisory Group

The Registry Platform secretariat was formally established on August 1, 2005 to implement World Health Assembly Resolutions 3.2 and 4.3, contained in WHA58.34, which called on the World Health Organization to:

> 3.2 establish a **voluntary platform to link clinical trials registers in order to ensure a single point of access and the unambiguous identification of trials** with a view to enhancing access to information by patients, families, patient groups and others;

And requested the Director-General to:

> 4.3 pursue with interested partners the development of a voluntary platform to link clinical trials registers

The Registry Platform staff is responsible for developing all necessary policies and procedures, and for implementing them to achieve a successful International Clinical Trials Registry Platform. The secretariat consults widely in developing its plans. Many of the consultations are with members of the project's Scientific Advisory Group (SAG) and International Advisory Board (IAB), but many consultations include other people who do not serve on either the SAG or the IAB. The project has also requested and received Open Comments from the general community.

The charge to the SAG is to provide advice to the Registry Platform project on its policies, priorities, and approaches. The 19 SAG members were selected to include international representation from the key stakeholder and expert groups, including researchers, patients, funders, ethics review boards, biomedical journals, pharmaceutical companies, and trial registers. Although the advice of the SAG is not binding on the Registry Platform secretariat, the consensus opinion of the SAG will very strongly shape the final form of the Registry Platform's activities.

Executive Summary

The WHO International Clinical Trials Registry Platform sets international norms and standards for trial registration and reporting worldwide. The Registry Platform's Scientific Advisory Group (SAG) met in Geneva on 17 and 18 November, 2005 to provide advice on the scientific and ethical aspects of proposed policies.

The SAG discussions were spirited, thoughtful, and well-informed. The SAG supported the key elements of the secretariat's proposed policies for an international system of trial registration. Specifically, the SAG

- Stated that the registration of all interventional trials is a scientific, ethical, and moral responsibility. All interventional trials in humans or groups of humans that are aimed at assessing health and health care interventions should be registered.
- Finalized the 20 minimum data items required for trial registration, and stated that full disclosure of the 20 items at the time of registration is critical on scientific grounds and is in the public interest.
- Supported the general structure and composition of an international network of such registers.
- Supported the importance of detecting multiply-registered trials.

The majority of SAG members supported the assignment of a Universal Trial Reference Number (UTRN) to unambiguously identify unique trials and to cross-reference trial entries across multiple registers. Time constraints precluded full discussion on membership criteria for trial registers.

A. Which Trials Should be Registered?

The registration of all interventional trials is a scientific, ethical, and moral responsibility. An interventional trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc." Further,

- All interventional trials in humans or groups of humans aimed at assessing health and health care interventions should be registered
- The WHO should continue to develop further norms and standards for trial registration to facilitate this process globally as quickly as possible

The Scientific Advisory Group considers it critical on scientific grounds, and in the public interest, that all 20 items in the Trial Registration Data Set be fully disclosed at the time of registration.

B. Trial Registration Data Set*

We include below the Trial Registration Data Set agreed upon by the SAG. For a trial to be properly registered, items #3 through #20 must be reported to a Member Register, unless data are not available (eg, secondary Trial ID). Some SAG members advocated for additional items, but it was agreed that the 20 items would be fixed at this time. The old Item 11 *Research Ethics Review* was replaced by *Countries of Recruitment* for a number of reasons. It was agreed that ethics approval should already be mandatory for all clinical trials, and asking for this information would thus be redundant. The requested information would also be of limited value, particularly for trials registered prior to ethics approval. Information about countries of recruitment was felt to be more useful for a variety of constituencies, and will be increasingly relevant as more trials are conducted in developing countries.

Further details of implementation will be agreed between Member Registers and the Registry Platform, and will be made available in a WHO guidance document.

	Item	Field Value	Definition/Explanation
1.	**Primary Register and Trial ID #**	Trial ID #	Select name of Member Register in which this trial was first registered (the trial's "Primary Register"), and that register's registry-issued unique ID assigned to this trial.
2.	**Date of Registration in Primary Register**		Date when trial was officially registered in the Primary Register DD/MM/YYY.
3.	**Secondary ID#s**	Issuing Authority ID Number Click to add more …	Other identifying numbers and issuing authorities besides the Primary Register, if any. Include the sponsor name and sponsor-issued trial number (e.g., protocol number) if available. Also include other member and non-member trial registers that have issued a number to this trial. There is no limit on the number of Secondary ID numbers that can be provided.

4.	**Source(s) of Monetary or Material Support**	Name Click to add more…	Major source(s) of monetary or material support for the trial (e.g., funding agency, foundation, company).
5.	**Primary Sponsor**	Name	The individual, organization, group or other legal person taking on responsibility for securing the arrangements to initiate and/or manage a study (including arrangements to ensure that the design of the study meets appropriate standards and to ensure appropriate conduct and reporting). The primary sponsor is normally the main applicant for regulatory authorization to begin the study. It may or may not be the main funder.
6.	**Secondary Sponsor(s)**	Name	Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship. A secondary sponsor may have agreed o to take on all the responsibilities of sponsorship jointly with the primary sponsor; or o to form a group with the primary sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or o to act as the sponsor's legal representative in relation to some or all of the trial sites o to take responsibility for the accuracy of trial registration information submitted
7.	**Contact for Public Queries**	Email, telephone number, or address	Email address, telephone number, or address of the contact who will respond to general queries, including information about current recruitment status
8.	**Contact for Scientific Queries**	Email, telephone number, or address Affiliation	Email address, telephone number, or address, and affiliation of the person to contact for scientific inquiries about the trial (e.g., principal investigator, medical director for the study at the sponsor). For a multi-center study, enter the contact information for the lead Principal Investigator or overall medical director.
9.	**Public Title**		Title intended for the lay public in easily understood language.
10.	**Scientific Title**	Acronym	*The SAG did not reach agreement on this item during the Advisory Group meeting.*
11.	**Countries of Recruitment**		The countries from which participants will be, are intended to be, or have been

			recruited (as last reported to the Primary Register).
12.	**Health Condition(s) or Problem(s) Studied**		Primary health condition(s) or problem(s) studied (e.g., depression, breast cancer, medication error). Enter one term per line in the field.
13.	**Intervention(s)**	Intervention name(s) Other details (e.g., dose, duration, etc) Click to add more experimental interventions… Control Intervention name Other details of control (e.g., dose, duration, etc.) Click to add more control interventions…	Enter the specific name of the intervention(s) and the comparator/control being studied, one at a time. Use the International Non-Proprietary Name if possible (not brand/trade names). For an unregistered drug, the generic name, chemical name, or company serial number is acceptable). If the intervention consists of several separate treatments, list in one line separated by commas (e.g., "low-fat diet, exercise"). For multi-armed studies, describe the intervention(s) for each arm in separate entries. The control intervention(s) is/are the interventions against which the study intervention is evaluated (e.g., placebo, no treatment, active control). If an active control is used, be sure to enter in the name(s) of that as well, or enter "placebo" or "no treatment" as applicable for the control arm. For each intervention, describe other intervention details as applicable (dose, duration, mode of administration, etc)
14.	**Key Inclusion and Exclusion Criteria**	Inclusion Criteria Exclusion Criteria	Inclusion and exclusion criteria for participant selection, including age and sex.
15.	**Study Type**	Single group study? If a multiple group study, is it randomized?	A single group study is one in which all participants are given the same intervention. Trials in which participants are assigned to receive one of two or more interventions are NOT single group studies. Crossover trials are NOT single group studies. For multiple group studies (2 or more study groups), a trial is "randomized" if participants are/were assigned to intervention groups by a method based on chance.
16.	**Date of First Enrollment**		Anticipated or actual date of enrollment of the first participant (MM/YYYY).
17.	**Target Sample Size**		Number of participants that this trial plans to or had planned to enroll as last reported to the Primary Register.

18.	**Recruitment Status**		Recruitment status of this trial, as last reported to the Primary Register. o Pending: participants are not yet being recruited or enrolled at any site o Active: participants are currently being recruited and enrolled o Temporary halt: there is a temporary halt in recruitment and enrollment o Closed: participants are no longer being recruited or enrolled
19.	**Primary Outcome(s)**	Outcome Name Timepoints Click to add more outcomes…	Outcomes are events, variables, or experiences that trial investigators measure because it is believed that they may be influenced by the intervention or exposure. The Primary Outcome should be the outcome used in sample size calculations, or the main outcome(s) used to determine the effect of the intervention(s). Enter the names of all primary outcomes of the trial, one at a time. Be as specific as possible (e.g., "Beck depression score" rather than just "depression"). For each outcome, also provide all the timepoints at which it is to be measured. Examples: Outcome Name: all cause mortality, Timepoints: one year; or Outcome Name: Beck depression score, Timepoint: 6,12, and 18 weeks
20.	**Key Secondary Outcomes**	Outcome Name Timepoints Click to add more outcomes…	Outcomes are events or experiences that trial investigators measure because it is believed that they may be influenced by the intervention or exposure. Secondary outcomes are events or experiences other than the primary outcome(s) that will be used to evaluate the intervention(s), and that are specified in the study protocol. Enter the name of each secondary outcome measure of the trial, one at a time. Also provide all the timepoints at which this outcome is to be measured. Examples: Outcome Name: cardiovascular mortality, Timepoint: 6 months; or Outcome Name: functional status, Timepoint: 4 and 8 weeks

* All entries should accurately reflect the study protocol. If the study was approved by an ethics review board, entries should reflect the study protocol that received final approval from the ethics board.

C. Network of Member Registers

C.1 Network Structure

The Registry Platform seeks to develop common rules and expectations for registers, to achieve the following objectives:

- Achieve the registration of all interventional trials worldwide
- Make it easy for Responsible Registrants[1] and the public to know which registers meet international standards of acceptability
- Ensure that each trial is registered in the fewest number of registers necessary to meet applicable local and regional regulations, and is registered once and only once in any one register

To meet these objectives, the Registry Platform should establish a network of internationally acceptable registers ("Member Registers") that together are comprehensive but that minimize overlap. "Responsible Registrants" can register their trials *directly* or *indirectly* (see below) with Member Registers.

C.1.A Advice on composition of the network

Any register meeting WHO register membership criteria should be eligible to become a Member Register.

Member Registers: We expect that Member Registers will mainly be national or regional registers. Ideally, they will serve non-overlapping communities (defined as those that share language, regulatory, and/or cultural factors), but will agree to cooperate in areas of potential overlap. Individual countries, regions, or international scientific groupings may choose to form partnerships with existing registers or to develop their own registers. In the interests of minimizing the chance of duplicate registration and of conserving resources, the WHO should encourage the formation of the minimum number of Member Registers necessary to serve global needs.

Non-Member Registers: There exist many trial registers worldwide whose organizers may not wish their register to serve as a Member Register, or which may not qualify as a Member Register. These registers may serve other important functions, however. For example, a university may sponsor a register to increase participant recruitment in its own trials, or a disease-specific register may provide a central repository in which investigators can register their trials related to interventions for that disease.

Non-member registers should establish an agreement with a single Member Register to ensure that the trial is affiliated with only one Member Register. Non-member registers that establish a satisfactory formal agreement with a Member Register (criteria to be defined) should be designated Associate [Member] Registers of the WHO Registry Platform. Responsible Registrants may enter the Trial Registration Data Set in a Member Register (*direct registration*) and have that information sent to a non-member register, or the data could be entered first into an Associate Register and then be uploaded to the Member Register (*indirect registration*).

[1] The "Responsible Registrant" for a trial is either the principal investigator (PI) or the primary sponsor, to be decided by an agreement between the parties. The primary sponsor is "the individual, organization, group or other legal person taking on responsibility for securing the arrangements to initiate, manage and finance a study", and is ultimately accountable for ensuring that the trial is properly registered. For multi-center and multi-sponsor trials, it is the lead PI or lead sponsor who should take responsibility for registration. The responsible registrant should make every reasonable effort to ensure that a trial is registered once and only once in any one register, and that the trial is registered in the fewest number of registers necessary to meet applicable regulations

C.1.B Advice on operation of the network

The WHO should assist the appropriate parties in each member state (e.g., Member Registers, national authorities, journal editors) to issue clear guidance on the appropriate member register for Responsible Registrants in their region. The guidance will change as new Associate Register agreements are formed and as national and regional registers begin operation.

Responsible Registrants should enter the Trial Registration Data Set for an individual trial only once (including multicenter trials). Thereafter, the Trial Registration Data Set for that trial should be exchangeable electronically among all trial registers worldwide.

C.2 Membership Criteria

A draft set of membership criteria was circulated, but there was insufficient time for discussion during the SAG meeting.

D. Trial Deduplication

D.1 Background

One of the goals of the Registry Platform is to provide an unambiguous method for identifying individual trials worldwide. Achieving this goal is complicated because trials may be registered in more than one register, particularly as local regulations may require registration in non-member or multiple registers.

The process of deduplication requires skilled personnel assisted by computer programs that, at best, identify pairs of trials that *might* be duplicates. There is little research or evaluation on the accuracy of these computer systems, or on the overall accuracy of the process. In many cases, a human expert has to contact the providers of the records to resolve uncertainties, a labor-intensive process that can take considerable time. Familiarity with local sponsors, organizations, languages, etc. would be essential in many cases, complicating deduplication efforts for trials conducted in those countries.

The SAG endorses Registry Platform policies that will help to minimize the risk of duplicate trial registration. Platform policy should:

- Clearly identify the Responsible Registrant, and assign to the Responsible Registrant the responsibility for minimizing duplicate registration
- Define what constitutes a unique trial
- Standardize the Trial Registration Data Set to facilitate comparisions between register entries
- Provide a network structure of Member Registers that minimizes the overlap of constituencies, and increases the likelihood that Responsible Registrants register each trial without duplication
- Encourage new Member Registers to develop only if required to meet global registration needs
- Require Member Registers to perform deduplication of entries within their own registers
- Provide Member Registers a forum for sharing and developing best practices on deduplication and quality assurance
- Provide training and capacity building for trial registration worldwide

The SAG believes that the primary preventive strategy against duplicate registration is to assign an identifier to a trial at the earliest possible time, e.g., at the time of submission to the first

ethics review board for that trial. Thereafter, all ethics submissions, participant enrollment, registrations, publications, etc. should use the initially assigned identifier. The logistics of implementing such a system both locally and globally are daunting, however. The SAG suggests that the WHO explore ways to assign a trial identifier as early in the trial registration process as possible, including the potential integration of ethics review and trial registration.

D.1.A Definition of Unique Trial

A trial is considered a "unique" trial if it is conducted according to a single document (the protocol) that describes its objective(s), design, methodology, statistical considerations, and organization. A multi-center trial is one that is conducted according to a single protocol but carried out at more than one site. Even if different versions of the protocol are implemented at each of the sites in a multi-center trial, they are all part of one unique trial and do not constitute separate trials.[2]

D.1.B Implementation of Trial Deduplication

The SAG appreciates the importance of trial deduplication, at the same time as it recognizes the difficulties. The SAG supports the approach of breaking the deduplication task down into two levels:

1. Local Deduplication: The best strategy for deduplication is prevention. Member Registers should verify that each new addition to its own register is not likely to be for a trial that has already been registered *within* that same register. Many existing registers already do local deduplication. All deduplication results should be shared with all involved parties (registers and registrants) so that future duplicate registration may be reduced. Member Registers should exchange information about experiences and approaches, so as to improve their overall deduplication performance.
2. Global Deduplication: No entity currently performs deduplication of register entries *across* registers. The SAG favors the WHO taking on this task, by providing a clearinghouse database for entries from all Member Registers, and working with existing groups who have extensive knowledge and prior experience with deduplication to develop best practices.

In partnership with registers administrators and other experts, the WHO should continue to investigate methods for quicker and more accurate deduplication, including but not limited to computational approaches, data standardization and coding, and manual approaches.

D.1.C Universal Trial Reference Number

Global deduplication will be the responsibility of WHO, which will compare each register entry against entries from all other registers. The SAG considered various approaches to doing this. One possibility is to run a web-based search across all Member registers to identify register entries that appear to be associated with each trial.

A large majority of the SAG endorsed the WHO assigning a Universal Trial Reference Number (UTRN) to each unique trial as determined by the process of global deduplication. This reference number serves a function -- cross-referencing entries across trial registers -- that no existing number does. Varying views were expressed regarding the utility of a UTRN. The majority view was that the overall benefits of having one global reference number for each trial that is determined (as best we can) to be unique outweighs other potential issues related to the introduction of a new number. The minority opinion was that a new number would introduce more confusion than not.

It is unclear how much time the process of global deduplication will take. The WHO should aim for the quickest turnaround possible, combined with the desired level of accuracy. A trial should be considered fully registered when it is registered in the Primary Register, so that assignment of the UTRN will not delay the initiation of recruitment for a trial. The UTRN should be relayed back to all registers and registrants affiliated with the trial.

E. Coding and Data Interchange

E.1 Coding of Trial Registration Data Set Items

Coding the values of key items in the Trial Registration Data Set (e.g., Item 13 Intervention name, Item 12 Health condition or problem studied, and Item 19 Primary Outcome Measure(s)) using standard vocabularies will allow for precise searching, which will be increasingly important as more trials are registered. The WHO should consider coding key fields of the Trial Registration Data Set and returning the coded terms to the Member Registers. The WHO should continue to consult coding experts to develop an approach to maximizing the utility of register entries in Member Registers.

Concern was raised by some SAG members that registering all interventional trials would result in a "clogged system" overwhelmed by many small, early phase studies. The fear was that potential trial participants may search for trials on a particular health condition and identify early phase studies that are not of interest. However, if certain fields in the Trial Data Set are coded using standard vocabulary that has a hierarchy of related concepts (e.g., MeSH), search portals can filter out trials with characteristics typical of early phase studies, and thus filter out unwanted trials.

E.2 Data Interchange Standards

Responsible Registrants will enter the Trial Registration Data Set only once, and that thereafter, the information should be exchangeable electronically among all relevant data systems. To achieve this data interchange, the Registry Platform should define a data interchange standard reflecting the Trial Registration Data Set, but only after due diligence in exploring and harmonizing with related information standards that already exist. These standards include those by HL-7, CDISC, and the BRIDG group, EMEA, and others from both the commercial and non-profit sectors. Care should also be taken to set the technical complexity of the standard at a level appropriate to need, and to provide technical assistance to registers (e.g., from developing countries) that may not have the technical expertise to implement the data interchange standard.

Glossary

Interventional Clinical Trial	Any research study that prospectively assigns human participants or groups of humans to one or more health-related intervention to evaluate the effect on outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioral approaches, process-of-care changes, preventive care, diagnostic procedures.
Data Interchange Standard	A set of rules for sending information between machines. Includes agreement and standardization on the concepts exchanged (e.g., "primary sponsor"), and agreement and standardization on the structure of the actual message that is exchanged.
Deduplication	The process of determining whether two sets of trial information belong to the same trial or whether they belong to 2 *unique trials* (see below). Deduplication can happen within registers (local deduplication), as well as among registers (global deduplication).
Direct Registration	Occurs when a Responsible Registrant submits the Trial Registration Data Set of a trial to a Member Register for the purpose of registering that trial
Indirect Registration	Occurs when a Responsible Registrant submits the Trial Data Set of a trial to an Associate Member Register, which then forwards that Data Set to the appropriate Member Register for registration of that trial
Member Register	A register that meets all Registry Platform criteria for international acceptability. Member Registers belong to the Network of Member Registers.
Primary Register	The Member Register in which a trial is first registered.
Responsible Registrant	The "Responsible Registrant" for a trial is either the principal investigator (PI) or the primary sponsor, to be decided by an agreement between the parties. The primary sponsor is "the individual, organization, group or other legal person taking on responsibility for securing the arrangements to initiate, manage and finance a study" (as defined in Trial Registration Data Set), and is ultimately accountable for ensuring that the trial is properly registered. For multi-center and multi-sponsor trials, it is the lead PI or lead sponsor who should take responsibility for registration. The responsible registrant should make every reasonable effort to ensure that a trial is registered once and only once in any one register, and that the trial is registered in the fewest number of registers necessary to meet applicable local and regional regulations.
Standard Vocabulary	A set of terms covering a domain of knowledge (e.g., medicine) that can be used as a shared way to describe that domain of knowledge. The terms may be related to each other in meaningful ways.

Unique ID	A unique identifier assigned by a register to each of its entries to identify individual register entries. With local deduplication, the register-issued unique ID will usually relate to a single, unique trial. However, if that trial is also registered in another register, the trial will also have another register-issued unique ID assigned by the other register. Thus, a register-issued ID will usually relate to a single, unique trial within that register but a single, unique trial may have more than one register-issued unique ID.
Unique Trial	A trial is considered a single trial if it is conducted according to a single document (the protocol) that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. A multi-center trial is one that is conducted according to a single protocol but carried out at more than one site. Even if different versions of the protocol are implemented at each of the sites in a multi-center trial, they are all part of one trial and do not constitute separate trials
UTRN	Universal Trial Reference Number, a number that the WHO Registry Platform issues for each trial deemed to be unique across Member Registers. The UTRN would be used to cross-reference entries for that same trial across multiple registers. Each single, unique trial will have one UTRN, and each UTRN will relate to a single, unique trial worldwide.

Scientific Advisory Group – Full List of Board Members (19)

as of November, 2005

Co-Chairs (2)

- **Kay Dickersin**, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- **Richard Horton**, The Lancet, London, United Kingdom

Members (17)

- **Gerd Antes**, Deutsches Cochrane Zentrum, Freiburg, Germany
- **Chris Chute**, Mayo Clinic, Rochester, Minnesota, United States of America
- **Francis P. Crawley**, Good Clinical Practice Alliance, Kessel-Lo, Belgium
- **Jeffrey M. Drazen**, New England Journal of Medicine, Boston, Massachusetts, United States of America
- **Davina Ghersi**, NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
- **Anne Greenwood**, Current Science Group, London, United Kingdom
- **Karmela Krleza-Jeric**, Randomised Controlled Trials, Canadian Institutes of Health Research, Ottawa, Ontario, Canada
- **Rebecca Kush**, Clinical Data Interchange Standards Consortium (CDISC), Austin, Texas, United States of America
- **David Moher**, Chalmers Research Group, The Children's Hospital of Eastern Ontario, Ottawa, Canada
- **Philip David Noguchi**, AMGEN, Washington, D.C., United States of America
- **Frank W. Rockhold**, GlaxoSmithKline, United States of America
- **Toshiro Tango**, National Institute of Public Health, Japan
- **Marc Taylor**, UK Department of Health, Leeds, United Kingdom
- **Jimmy Volmink**, University of Cape Town, Cape Town, South Africa
- **Liz Wager**, Sideview Consulting, Bucks, United Kingdom
- **Janet Wale**, Cochrane Consumer Network (CCNet), Burwood, VIC, Australia
- **Deborah Zarin**, ClinicalTrials.gov, Bethesda, Maryland, United States of America

FACT SHEET（抄訳）

ClinicalTrials.gov への登録：
Public Law 110-85, Title VIII で定めるところによる

2007 年 9 月 27 日に公衆衛生法を改正する公法 110-85 が施行され、ClinicalTrials.gov に登録すべき試験の種類が拡大された。それとともに、提出すべき登録項目が増え、結果情報の提出が必要になった他、法に従わない場合の罰則も定められた。新たに登録が必要になった事項には、2007 年 12 月 26 日が締切のものもある。結果情報の提出要件は、近日中に示される予定。

1．　一般的要求事項

A.　ClinicalTrials.gov に登録が必要な臨床研究（適用対象となる臨床研究）

・　医薬品・生物由来製品の研究：FDA 規制の対象となる医薬品等の比較対照試験。ただし、Phase I 試験を除く。

・　医療機器の研究：FDA 規制の対象となる機器の医療効果を見るための比較試験。ただし、小規模なフィージビリティ試験及び小児市販後調査を除く。

B.　試験登録の責任は誰にあるか。

1．　臨床試験のスポンサー　又は、

2．　臨床試験の主任研究者としてスポンサー等から指名された者

C.　求められるデータ

適用対象となる臨床試験を登録する際に、責任ある当事者は、記述的、募集、場所、連絡先、管理情報を提出しなければならない。主要・副次的指標、試験開始日、目標症例数が新たに要件に含まれることになった。

2．　ClinicalTrials.gov への登録のタイミング

一般に、適用対象となる臨床試験の責任ある当事者は、2007 年 12 月 26 日又は最初の患者の組み入れから 21 日後のいずれか遅い方までに、必要な情報を提出しなければならない。

例外：(a) 2007 年 9 月 27 日時点で実施中の臨床試験で、重篤又は致死的な疾患又は症状を含まないものについては、2008 年 9 月 27 日までに登録する。

(b) 重篤又は致死的な疾患又は症状を含む試験で、2007 年 9 月 27 日以前に開始されたもの、及び 2007 年 12 月 26 日以前に完了したものは、新法施

行前に行われていた登録要件の対象となることはあっても、新規要件の対象にはならない。

3．　登録しなかった場合の罰則

適用対象となる臨床試験を登録しなかった場合の、責任ある当事者への罰則は重大で、民事上の罰金刑及び連邦から資金提供を受けて行っている試験の場合は、研究費の保留又は返還を含む。2007年12月26日以降、連邦医薬品食品化粧品法第505条、510(k)条、515条、520(m)条、又は公衆衛生法第351条に基づきFDAに提出される申請書又は報告書については、適用条項を遵守している旨の証明書の添付が必要となる。

11/09/07

FACT SHEET (Available at http://prsinfo.clinicaltrials.gov/)

Registration at ClinicalTrials.gov: As required by Public Law 110-85, Title VIII

On September 27, 2007, a U.S. law was enacted that expands the types of clinical trials that must be registered in ClinicalTrials.gov, increases the number of data elements that must be submitted, and also requires submission of results data. There are penalties for non-compliance with the law. This fact sheet addresses the new registration requirements, some of which have reporting deadlines beginning on **December 26, 2007.** Information about the requirement to submit results data will be forthcoming.

1. General Requirements for Registration

A. Clinical Trials That Must be Registered at ClinicalTrials.gov ("Applicable Clinical Trials")

- Trials of Drugs and Biologics: controlled clinical investigations, other than Phase 1 investigations, of a product subject to FDA regulation [1]
- Trials of Devices: Controlled trials with heath outcomes of devices subject to FDA regulation, other than small feasibility studies, and pediatric postmarket surveillance [2]

B. Who is Responsible for Trial Registration? ("Responsible Party") [3]

1. The sponsor of the clinical trial [4]; - *OR* -
2. The principal investigator (PI) of such clinical trial if so designated by a sponsor, grantee, contractor, or awardee, so long as the PI is responsible for conducting the trial and has sufficient data rights.

C. Required Data Elements -

The Responsible Party must submit descriptive, recruitment, location, contact, and administrative information when registering an applicable clinical trial [5]. More data elements are required than under prior U.S. law, and these new requirements include primary and secondary outcome measures, start date, and target number of subjects.

2. Timing of Registration at ClinicalTrials.gov

In general, the Responsible Party for an applicable clinical trial must submit required information by the later of 12/26/**2007** or 21 days after the first patient is enrolled [6].

Exceptions: (a) data for trials "ongoing" as of 9/27/2007 that do ***not*** involve a "serious or life threatening disease or condition" must be submitted by 9/27/**2008** [7], [8];
(b) trials that involve a "serious or life threatening disease or condition", are initiated before 9/27/07, and have a "completion date" prior to 12/26/2007 [9] are not subject to the new requirements, although they may be subject to other laws.

3. Penalties for Failure to Register

Penalties for responsible parties who fail to register applicable clinical trials are significant and may include civil monetary penalties [10] and, for federally-funded trials, the withholding or recovery of grant funds [11]. Starting December 26, 2007, any application or report submitted to FDA under sections 505, 510(k), 515, or 520(m) of the Federal Food, Drug, and Cosmetic Act or under section 351 of the Public Health Service Act will need to include certification of compliance with any applicable provisions [12].

FACT SHEET

Registration at ClinicalTrials.gov:
As required by Public Law 110-85, Title VIII

ENDNOTES

1. "`(iii) APPLICABLE DRUG CLINICAL TRIAL-

`(I) IN GENERAL- The term `applicable drug clinical trial' means a controlled clinical investigation, other than a phase I clinical investigation, of a drug subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to section 351 of this Act. [The Public Health Service Act]

`(II) CLINICAL INVESTIGATION- For purposes of subclause (I), the term `clinical investigation' has the meaning given that term in section 312.3 of title 21, Code of Federal Regulations (or any successor regulation).

`(III) PHASE I- For purposes of subclause (I), the term `phase I' has the meaning given that term in section 312.21 of title 21, Code of Federal Regulations (or any successor regulation)."

[PL 110-85, Section 801(a), adding new 42 U.S.C. 282(j)(1)(A)(iii)]

2. "`(ii) APPLICABLE DEVICE CLINICAL TRIAL- The term `applicable device clinical trial' means--

`(I) a prospective clinical study of health outcomes comparing an intervention with a device subject to section 510(k), 515, or 520(m) of the Federal Food, Drug, and Cosmetic Act against a control in human subjects (other than a small clinical trial to determine the feasibility of a device, or a clinical trial to test prototype devices where the primary outcome measure relates to feasibility and not to health outcomes); and

`(II) a pediatric postmarket surveillance as required under section 522 of the Federal Food, Drug, and Cosmetic Act."

[PL 110-85, Section 801(a), adding new 42 U.S.C. 282(j)(1)(A)(ii)]

3. "`(ix) RESPONSIBLE PARTY- The term `responsible party', with respect to a clinical trial of a drug or device, means--

`(I) the sponsor of the clinical trial (as defined in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation)); or

"`(II) the principal investigator of such clinical trial if so designated by a sponsor, grantee, contractor, or awardee, so long as the principal investigator is responsible for conducting the trial, has access to and control over the data from the clinical trial, has the right to publish the results of the trial, and has the ability to meet all of the requirements under this subsection for the submission of clinical trial information."

[PL 110-85, Section 801(a), adding new 42 U.S.C. 282(j)(1)(A)(ix)]

4. Under 21 C.F.R. 50.3, "Sponsor" is defined as "a person who initiates a clinical investigation, but who does not actually conduct the investigation, i.e., the test article is administered or dispensed to or used involving, a subject under the immediate direction of another individual. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct a clinical investigation it has initiated is considered to be a sponsor (not a sponsor-investigator), and the employees are considered to be investigators."

5. "`(ii) CONTENT- The clinical trial information required to be submitted under this paragraph for an applicable clinical trial shall include--

`(I) descriptive information, including--
`(aa) a brief title, intended for the lay public;
`(bb) a brief summary, intended for the lay public;
`(cc) the primary purpose;
`(dd) the study design;
`(ee) for an applicable drug clinical trial, the study phase;
`(ff) study type;
`(gg) the primary disease or condition being studied, or the focus of the study;
`(hh) the intervention name and intervention type;
`(ii) the study start date;
`(jj) the expected completion date;
`(kk) the target number of subjects; and
`(ll) outcomes, including primary and secondary outcome measures;

`(II) recruitment information, including--
`(aa) eligibility criteria;
`(bb) gender;
`(cc) age limits;
`(dd) whether the trial accepts healthy volunteers;
`(ee) overall recruitment status;
`(ff) individual site status; and
`(gg) in the case of an applicable drug clinical trial, if the drug is not approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of this Act, specify whether or not there is expanded access to the drug under section 561 of the Federal Food, Drug, and Cosmetic Act for those who do not qualify for enrollment in the clinical trial and how to obtain information about such access;

`(III) location and contact information, including--
`(aa) the name of the sponsor;
`(bb) the responsible party, by official title; and
`(cc) the facility name and facility contact information (including the city, State, and zip code for each clinical trial location, or a toll-free number through which such location information may be accessed); and

`(IV) administrative data (which the Secretary may make publicly available as necessary), including--
`(aa) the unique protocol identification number;
`(bb) other protocol identification numbers, if any; and
`(cc) the Food and Drug Administration IND/IDE protocol number and the record verification date."

[PL 110-85, Section 801(a), (adding new 42 U.S.C. 282(j)(2)(A)(ii))]

6. "`(C) DATA SUBMISSION- The responsible party for an applicable clinical trial, including an applicable drug clinical trial for a serious or life-threatening disease or condition, that is initiated after, or is ongoing on the date that is 90 days after, the date of the enactment of the Food and Drug Administration Amendments Act of 2007, shall submit to the Director of NIH for inclusion in the registry data bank the clinical trial information described in of subparagraph (A)(ii) not later than the later of--

`(i) 90 days after such date of enactment;

`(ii) 21 days after the first patient is enrolled in such clinical trial; or

`(iii) in the case of a clinical trial that is not for a serious or life-threatening disease or condition and that is ongoing on such date of enactment, 1 year after such date of enactment."

[PL 110-85, Section 801(a), (adding new 42 U.S.C. 282(j)(2)(C))]

7. "`(viii) ONGOING.—The term 'ongoing' means, with respect to a clinical trial of a drug or a device and to a date, that—

`(I) 1 or more patients is enrolled in the clinical trial; and

`(II) the date is before the completion date of the clinical trial.

[PL 110-85, Section 801(a), (adding new 42 U.S.C. 282(j)(1)(A)(viii))]

8. Consistent with current FDA and ClinicalTrials.gov guidance, the NIH interprets "serious and life-threatening disease or condition to mean: (1) diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and (2) diseases or conditions with potentially fatal outcomes, where the endpoint of clinical trial analysis is survival.

The seriousness of a disease is a matter of judgment, but generally is based on such factors as survival, day-to-day functioning, and the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. For example, acquired immunodeficiency syndrome (AIDS), all other stages of human immunodeficiency virus (HIV) infection, Alzheimer's disease, angina pectoris, heart failure, cancer, and many other diseases are clearly serious in their full manifestations. Furthermore, many chronic illnesses that are generally well managed by available therapy can have serious outcomes. For example, inflammatory bowel disease, asthma, rheumatoid arthritis, diabetes mellitus, systemic lupus erythematosus, depression, psychoses, and many other diseases can be serious in some or all of their phases or for certain populations.

Any investigational drug that has received fast track designation by the FDA is considered a drug to treat a serious disease or condition.

9. "(v) COMPLETION DATE.—The term 'completion date' means, with respect to an applicable clinical trial, the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical trial concluded according to the prespecified protocol or was terminated.

[PL 110-85, Section 801(a), adding new 42 U.S.C. 282(j)(1)(A)(v)]

10. "`(1) PROHIBITED ACTS- Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the following:

`(jj)(1) The failure to submit the certification required by section 402(j)(5)(B) of the Public Health Service Act, or knowingly submitting a false certification under such section.

`(2) The failure to submit clinical trial information required under subsection (j) of section 402 of the Public Health Service Act.

`(3) The submission of clinical trial information under subsection (j) of section 402 of the Public Health Service Act that is false or misleading in any particular under paragraph (5)(D) of such subsection (j).'

(2) CIVIL MONEY PENALTIES- Subsection (f) of section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333), as redesignated by section 226, is amended--

(A) by redesignating paragraphs (3), (4), and (5) as paragraphs (5), (6), and (7), respectively;

(B) by inserting after paragraph (2) the following:

`(3)(A) Any person who violates section 301(jj) shall be subject to a civil monetary penalty of not more than $10,000 for all violations adjudicated in a single proceeding.

`(B) If a violation of section 301(jj) is not corrected within the 30-day period following notification under section 402(j)(5)(C)(ii), the person shall, in addition to any penalty under subparagraph (A), be subject to a civil monetary penalty of not more than $10,000 for each day of the violation after such period until the violation is corrected.';

(C) in paragraph (2)(C), by striking `paragraph (3)(A)' and inserting `paragraph (5)(A)';

(D) in paragraph (5), as so redesignated, by striking `paragraph (1) or (2)' each place it appears and inserting `paragraph (1), (2),or (3)';

(E) in paragraph (6), as so redesignated, by striking `paragraph (3)(A)' and inserting `paragraph (5)(A)'; and

(F) in paragraph (7), as so redesignated, by striking `paragraph (4)' each place it appears and inserting `paragraph (6)'.

[PL 110-85, Section 801(b), adding new section 21 U.S.C. 331(jj)]

11. `(i) GRANTS FROM CERTAIN FEDERAL AGENCIES- If an applicable clinical trial is funded in whole or in part by a grant from any agency of the Department of Health and Human Services, including the Food and Drug Administration, the National Institutes of Health, or the Agency for Healthcare Research and Quality, any grant or progress report forms required under such grant shall include a certification that the responsible party has made all required submissions to the Director of NIH under paragraph (2) and (3).

`(ii) VERIFICATION BY FEDERAL AGENCIES- The heads of the agencies referred to in clause (i), as applicable, shall verify that the clinical trial information for each applicable clinical trial for which a grantee is the responsible party has been submitted under paragraph (2) and (3) before releasing any remaining funding for a grant or funding for a future grant to such grantee.

[PL 110-85, Section 801(a), adding new 42 U.S.C. 282(j)(5)(A)(i) and (ii)]

12. "(B) CERTIFICATION TO ACCOMPANY DRUG, BIOLOGICAL PRODUCT, AND DEVICE SUBMISSIONS.—At the time of submission of an application under section 505 of the Federal Food, Drug, and Cosmetic Act, section 515 of such Act, section 520(m) of such Act, or section 351 of this Act, or submission of a report under section 510(k) of such Act, such application or submission shall be accompanied by a certification that all applicable requirements of this subsection have been met. Where available, such certification shall include the appropriate National Clinical Trial control numbers.

[PL 110-85, Section 801(a), adding new 42 U.S.C. 282(j)(5)(B)]

臨床研究登録データベース
及び
ポータルサイトの構成

平成20年2月13日

臨床研究登録情報検索ポータル及び3登録データベース

【2008年3月1に本稼働:データ定期更新開始】

International Clinical
Trials Registry Platform

WHO

Japan Clinical Trial Registers Network（仮称）→WHOのプライマリーレジスター（登録機関）へ

UMIN　日本医師会　JAPIC

試験登録データ　試験登録データ　試験登録データ

Internet

厚生労働省　国立保健医療科学院

夜間等の負荷がかからない時に他機関システム更新データの複製

データベース

UMIN複製データ
医師会複製データ
JAPIC複製データ

◇基本情報項目の複製

各団体で登録された試験データの基本情報項目を複製します。

◇臨床研究情報検索機能
◇詳細情報は、各機関にアクセスし参照

WEBサーバ

各機関で独自に登録されている項目は詳細情報をリンクすると転送することにより、参照できます

一般市民
■HPへのアクセス
■臨床研究情報の検索
■臨床研究情報の参照

30

インターネット上の画面遷移図

1. トップ画面



「臨床研究(試験)検索画面へ」をクリック

2. 検索画面



入力し「検索」をクリック

3. 検索結果一覧画面



検索方法は2種類
①フリーワード検索
『自由にキーワードを入力して下さい』
②フィールド検索
『指定したい項目に入力して下さい』

三登録センターごとの
詳細画面を表示

4. 詳細画面







（1）トップ画面



（2）検索画面」へ遷移します。

FAQを掲載。

2008年3月1日より提供

臨床研究に臨床試験に関心が高そうな人達という想定をし、内容を選択し提示。

2008年3月1日より提供

32

（2）検索画面



「(3)検索一覧画面」へ遷移します。

（3）検索結果一覧画面


臨床研究(試験)情報検索 | 検索結果 - Microsoft Internet Explorer
ファイル(F) 編集(E) 表示(V) お気に入り(A) ツール(T) ヘルプ(H)
戻る 検索 お気に入り
アドレス(D)
移動
トップ 検索 検索結果
臨床研究(試験)情報検索
検索結果
全999ページ
<<先頭へ <前へ 11 12 13 14 15 16 17 18 19 20 次へ> 最後へ>>
もどる
結果一覧
閲覧 試験名▼▲ 対象疾患▼▲ 実施責任組織▼▲ 進捗状況▼▲ 登録日▼▲ ▼▲
詳細 骨粗鬆症に対する多剤併用療法の有効性に関する多施設共同ランダム化比較臨床研究―脊椎椎体圧迫骨折予防効果を指標とするアレンドロネートと活性型ビタミンD3の併用効果― 骨粗鬆症 日本骨粗鬆症学会/A-TOP研究会 参加者募集中 2005/07/01 UMIN
詳細 膠芽腫患者に対する自家腫瘍ワクチンを用いた臨床第I/IIa相共同研究 膠芽腫 東京女子医科大学 参加者募集中
詳細 アルガトロバンのヘパ 小板減少症に対する 血小板減少 塞栓症を併発 因性血小板減少症 参加者募集中 2005/12/21 日本医師会
詳細 静注用フェノバルビタールによる新生児のけいれんの有効性・安全性に関する研究 香川大学医学部附属病院 新生児けいれん 参加者募集中 2006/01/04 日本医師会
詳細 TM-411の多発性骨髄腫に対する第2相臨床試験 多発性骨髄腫 テムリック株式会社 Translational Medicinal Research Center Co.,Ltd 参加者募集中 JAPIC
詳細 オルメテック錠特定使用成績調査 本態性高血圧 三共株式会社 参加者募集 JAPIC
34
マイ コンピュータ
項目名▲▼をクリックするとソートします。
「（4）詳細画面」へ遷移します

（4）詳細画面－①（UMIN）


臨床研究(試験)情報検索 | 検索詳細 - Microsoft Internet Explorer
ファイル(F) 編集(E) 表示(V) お気に入り(A) ツール(T) ヘルプ(H)
戻る 検索 お気に入り リンク
アドレス(D) 移動
結果詳細
臨床研究(試験)情報検索
結果詳細[UMIN]
閉じる
この臨床研究(試験)は、他の登録センター(日本医師会またはJAPIC)にも登録されている可能性があります。
UMIN試験ID C000000001
UMINセンター臨床研究(試験)情報ページへ
公開日 2005/07/01
基本情報 試験名 骨粗鬆症に対する多剤併用療法の有効性に関する多施設共同ランダム化比較臨床研究―脊椎椎体圧迫骨折予防効果を指標とするアレンドロネートと活性型ビタミンD3の併用効果―
基本情報 試験簡略名 Japanese Osteoporosis Intervention Trial (JOINT) -02
基本情報 試験実施地域 日本
対象疾患 対象疾患 骨粗鬆症
評価 主要アウトカム評価 椎体の新規骨折の発生頻度
評価 副次アウトカム評価 新規骨折の発現時期、非椎体骨折発生頻度、骨量、QOL、血中ビタミンD濃度、安全性
試験デザイン 基本デザイン 並行群間比較
試験デザイン ランダム化 ランダム化<
介入 介入1 アレンドロネート(2年間)
介入 介入2 アレンドロネート＋活性型ビタミンD3(2年間)
年齢(下限) 70歳以上
年齢(上限)
ページが表示されました
35
マイ コンピュータ

（4）詳細画面－②（日本医師会）



（4）詳細画面－③（JAPIC）



今後の予定

	臨床研究（試験）登録情報を検索広報するポータルサイトの開発のための研究	仮運用	本稼働
時期	2005年度、2006年度	2007年10月1日～	2008年3月1日～
概要	国内の三登録センター（UMINセンター、日本医師会治験促進センター、JAPIC）に登録されている臨床研究(試験)情報の検索と、臨床試験に関する普及啓発を目的とし、臨床研究（試験）登録情報を検索広報するポータルサイトの設計と構築のための検討を行った。	本稼働準備のための仮運用開始。三登録センターより提供された登録データを事前に取り込み、日本語で利用できる一般国民（日本国民向け）を対象に、三登録センターに登録されているデータの串刺しポータル（検索）機能を提供する。 臨床研究（試験）情報検索機能	本稼働開始。3機関とのデータ連携を実現する。日時でデータ取得し、情報提供を行う（データ自動更新を定期的に行う）。臨床研究（試験）に関するまた知識の普及啓発の情報やよくある問い合わせをFAQとして提供する。 臨床研究（試験）に関する学習 FAQ
備考	UMIN、日本医師会、JAPIC、科学院　共同研究		臨床試験に関する学習（広報）に関しては、このサイトを訪れて臨床試験に関する知識を得ようとする一般市民を、臨床試験に関心が高そうな人達という想定をし、それらの人々が知りたい内容、知っておいてほしい内容という観点から内容を選択し提示する。